J&J’s largest India site to finally operate by 2018

pharmafile | December 20, 2016 | News story | Manufacturing and Production India, Johnson & Johnson 

Johnson & Johnson has reportedly announced that its manufacturing plant in Telangana, India, its largest site in the country, is due to be completed and fully operational by 2018, according to a top official knowledgeable on the matter.

The $85 million site is the company’s third in India and will boast the capacity to manufacture 18,000 tonnes of healthcare products including hygiene, skin and baby products. The facility was originally planned to be completed “by the end of 2016”; after several procedural delays, the company is confident that production will be completed by the new date and is currently working to get all the necessary approvals.

The first foundation stone for the 47 acre project was laid down by Telangana chief minister K Chandrasekhar Rao in September 2014. While the company overstepped its original deadline, it has already set aside $100 million for future expansion of the plant.

J&J’s Vikas Srivastava, managing director, India consumer business, was quoted in 2014 as saying: “It will create direct and indirect jobs to 1,500. The idea behind setting up this plant is to be close to south India, our largest market, which contributes 30-40% to our India business.”

This comes as good news for the company after a series of missteps, including huge payouts over damages caused by its hip implants and allegations its talcum powder product caused ovarian cancer in a number of women.

Matt Fellows

Related Content

Johnson & Johnson to acquire Shockwave Medical

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a …

FDA approves J&J’s Opsynvi for PAH treatment

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has …

Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn

Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx …

Latest content